Enzyme Inhibition in Drug Discovery and Development (eBook, PDF)

The Good and the Bad
Redaktion: Lu, Chuang; Li, Albert P.

• Format: PDF

Produktbeschreibung

The science and applied approaches of enzyme inhibition in drug discovery and development Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development. With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions--desirable pharmacological effects--and "bad" inhibitions--drug-drug interactions and toxicity. The book discusses: * The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment * The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug-drug interactions * The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 868
• Erscheinungstermin: 28. Januar 2010
• Englisch
• ISBN-13: 9780470538944
• Artikelnr.: 37296856

Autorenporträt

Chuang Lu, PhD, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug-drug interaction, and in vitro-in vivo correlation. Albert P. Li, PhD, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including Drug-Drug Interactions in Pharmaceutical Development, published by Wiley.

Inhaltsangabe

PREFACE. CONTRIBUTORS. PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES.
1. The Drug Discovery Process (Gerald T. Miwa). 2. Medicinal Chemistry of
the Optimization of Enzyme Inhibitors (Geraldine Harriman, Amy Elder, and
Indranath Ghosh). 3. Bioanalytical Technologies in Drug Discovery (Jing-Tao
Wu). 4. Safety Biomarkers in Drug Development: Emerging Trends and
Implications (Eric R. Fedyk). 5. The Role of Drug Metabolism in Drug
Discovery (Tonika Bohnert and Liang-Shang Gan). 6. Applied Pharmacokinetics
in Drug Discovery and Development (Hua Yang, Xingrong Liu, Anjaneya
Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu). PART
II. INHIBITION OF THE DRUG METABOLIZING ENZYMES--THE UNDESIRABLE
INHIBITION. 7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes
(R. Scott Obach). 8. Cytochrome P450 Induction (Edward L. LeCluyse, Michael
W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi). 9.
Inhibition of Drug-Metabolizing Enzymes in Gastrointestinal Tract and Its
Influence on the Drug-Drug Interaction Prediction (Aleksandra Galetin and
J. Brian Houston). 10. Enzyme Inhibition in Various In Vitro Systems (Ping
Zhou). 11. Cytochrome P450 Degradation and Its Clinical Relevance
(Mingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia).
12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus
on Enzyme Inhibition (Michael B. Fisher). 13. Evaluation of Inhibitors of
Drug Metabolism in Human Hepatocytes (Albert P. Li and Chuang Lu). 14.
Grapefruit Juice and Its Constituents as New Esterase Inhibitors (Suresh K.
Balani). 15. Transporter-Xenobiotic Interactions: An Important Aspect of
Drug Development Studies (Gang Luo, Richard Ridgewell, and Thomas
Guenthner). 16. Polymorphisms of Drug Transporters and Their Clinical
Implications (Cindy Q. Xia and Johnny J. Yang). 17. Clinical Drug
Interactions Due to Metabolic Inhibition: Prediction, Assessment, and
Interpretation (Lisa L. von Moltke and David J. Greenblatt). 18. Predicting
Interindividual Variability of Metabolic Drug-Drug Interactions:
Identifying the Causes and Accounting for Them Using Systems Approach (Amin
Rostami-Hodjegan). PART III. INHIBITION OF THE DRUG TARGET ENZYMES--THE
DESIRABLE INHIBITION. 19. NF-ºB: Mechanism, Tumor Biology, and Inhibitors
(Lenny Dang). 20. G-Protein-Coupled Receptors as Drug Targets (Wenyan Miao
and Lijun Wu). 21. Pharmacological Modulation of Ion Channels for the
Treatment of Chronic Pain (Yi Liu and Ning Qin). 22. Targeting the mTOR
Pathway for Tumor Therapeutics (Wei Chen). 23. HIV-1 Protease Inhibitors as
Antiretroviral Agents (Sergei V. Gulnik, Elena Afonina, and Michael
Eissenstat). INDEX.